XTX Topco Ltd Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Key Points

• XTX Topco Ltd purchased 216,228 shares of Xeris Biopharma Holdings, Inc. valued at approximately $1.187 million, representing a 0.14% ownership stake in the company.
• Xeris Biopharma's most recent financial report showed a narrower-than-expected loss of ($0.06) EPS, and revenue of $57.80 million, surpassing analyst predictions.
• Wall Street analysts have mixed ratings on Xeris Biopharma, with a consensus "Moderate Buy" rating and an average target price of $6.25 for the stock.

XTX Topco Ltd purchased a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 216,228 shares of the company's stock, valued at approximately $1,187,000. XTX Topco Ltd owned approximately 0.14% of Xeris Biopharma at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Xeris Biopharma by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock valued at $26,778,000 after acquiring an additional 133,738 shares during the period. Geode Capital Management LLC increased its holdings in shares of Xeris Biopharma by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company's stock worth $11,364,000 after purchasing an additional 17,956 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Xeris Biopharma by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock worth $7,115,000 after purchasing an additional 500,120 shares during the period. Millennium Management LLC increased its holdings in shares of Xeris Biopharma by 34.8% during the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock worth $6,606,000 after purchasing an additional 502,853 shares during the period. Finally, Nuveen Asset Management LLC increased its holdings in shares of Xeris Biopharma by 13.6% during the 4th quarter. Nuveen Asset Management LLC now owns 1,903,442 shares of the company's stock worth $6,453,000 after purchasing an additional 228,380 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Kevin Mcculloch bought 25,000 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The shares were bought at an average cost of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the transaction, the insider owned 1,708,585 shares of the company's stock, valued at approximately $7,483,602.30. This represents a 1.48% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.56% of the stock is owned by company insiders.

Xeris Biopharma Stock Down 0.6%

XERS traded down $0.04 during trading on Wednesday, hitting $5.45. 1,399,850 shares of the company's stock were exchanged, compared to its average volume of 2,426,072. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $6.07. The stock has a market cap of $851.49 million, a P/E ratio of -18.24 and a beta of 0.65. The business's 50 day moving average is $4.87 and its two-hundred day moving average is $4.52.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. On average, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Oppenheimer increased their price target on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $6.25.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.